Compare SIEB & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | UNCY |
|---|---|---|
| Founded | 1886 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.6M | 121.9M |
| IPO Year | N/A | 2021 |
| Metric | SIEB | UNCY |
|---|---|---|
| Price | $3.79 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 23.4K | ★ 384.0K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $90,289,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.39 | ★ N/A |
| Revenue Growth | ★ 8.32 | N/A |
| 52 Week Low | $2.08 | $3.71 |
| 52 Week High | $5.77 | $11.00 |
| Indicator | SIEB | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 72.02 | 57.10 |
| Support Level | $2.82 | $6.31 |
| Resistance Level | $3.05 | $6.95 |
| Average True Range (ATR) | 0.26 | 0.42 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 90.57 | 53.72 |
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.